Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
A275935-1mg | 1mg | In stock | $28.90 | |
A275935-5mg | 5mg | In stock | $117.90 | |
A275935-10mg | 10mg | In stock | $206.90 | |
A275935-25mg | 25mg | In stock | $465.90 | |
A275935-50mg | 50mg | In stock | $800.90 | |
A275935-100mg | 100mg | In stock | $1,335.90 |
Potent, selective, ATP competitive JNK inhibitor. Cell-permeable.
Synonyms | AS601245|345987-15-7|AS-601245|1,3-benzothiazol-2-yl(2-((2-(3-pyridinyl)ethyl)amino)-4-pyrimidinyl)acetonitrile|2-(benzo[d]thiazol-2-yl)-2-(2-((2-(pyridin-3-yl)ethyl)amino)pyrimidin-4-yl)acetonitrile|2-(1,3-benzothiazol-2-yl)-2-[2-(2-pyridin-3-ylethylamin |
---|---|
Specifications & Purity | ≥95% |
Storage Temp | Store at -20°C,Desiccated |
Shipped In | Dry ice |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of mitogen-activated protein kinase 10 |
Product Description | Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months. product description: A cell-permeable pyrimidinyl compound that displays anti-inflammatory properties. Acts as a potent, reversible, and ATP-competitive inhibitor of c-Jun N-terminal kinase (JNK, IC50 = 150, 220, and 70 nM for hJNK1, hJNK2, and hJNK3, respectively) with a 10- to 100-fold greater selectivity over a panel of 25 other commonly studied kinases (IC50 typically in the range of 1-10 µM or no effect at 10 µM). Its in vivo efficacy has been demonstrated in gerbils, mice, and rats via oral, i.v., or i.p. administration. Biochemical mechanism: Cell permeable: yes Product competes with ATP. Primary Target hJNK 1, hJNK 2, hJNK 3 Reversible: yes Target IC50: 150, 220, and 70 nM for hJNK1, hJNK2, and hJNK3, respectively |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 2-(1,3-benzothiazol-2-yl)-2-[2-(2-pyridin-3-ylethylamino)pyrimidin-4-yl]acetonitrile |
---|---|
INCHI | InChI=1S/C20H16N6S/c21-12-15(19-25-17-5-1-2-6-18(17)27-19)16-8-11-24-20(26-16)23-10-7-14-4-3-9-22-13-14/h1-6,8-9,11,13,15H,7,10H2,(H,23,24,26) |
InChi Key | RCYPVQCPYKNSTG-UHFFFAOYSA-N |
Canonical SMILES | C1=CC=C2C(=C1)N=C(S2)C(C#N)C3=NC(=NC=C3)NCCC4=CN=CC=C4 |
Isomeric SMILES | C1=CC=C2C(=C1)N=C(S2)C(C#N)C3=NC(=NC=C3)NCCC4=CN=CC=C4 |
PubChem CID | 10109823 |
Molecular Weight | 372.45 |
PubChem CID | 11422035 |
---|---|
ChEMBL Ligand | CHEMBL191384 |
CAS Registry No. | 345987-15-7 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
B2318670 | Certificate of Analysis | Dec 21, 2023 | A275935 |
B2318673 | Certificate of Analysis | Dec 21, 2023 | A275935 |
B2318688 | Certificate of Analysis | Dec 21, 2023 | A275935 |
B2318823 | Certificate of Analysis | Dec 21, 2023 | A275935 |
B2318880 | Certificate of Analysis | Dec 21, 2023 | A275935 |
B2318885 | Certificate of Analysis | Dec 21, 2023 | A275935 |
Solubility | Soluble in DMSO to 25 mM |
---|
1. Gaillard P, Jeanclaude-Etter I, Ardissone V, Arkinstall S, Cambet Y, Camps M, Chabert C, Church D, Cirillo R, Gretener D et al.. (2005) Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.. J Med Chem, 48 (14): (4596-607). [PMID:15999997] |
2. Ivshina MP et al.. (2022) CPEB1 regulates the inflammatory immune response, phagocytosis, and alternative polyadenylation in microglia.. Glia, 70 (10): (1850-1863). [PMID:35635122] |